Clinical trial
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to…
NCT00449072 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00449072 |
|---|---|
| Title | Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) |
| Official title | A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Perennial |
| Intervention type | Drug, Other |
| Interventions | Placebo, TAA-AQ, Nasacort® AQ, Claritin® |
| Enrollment | 299 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Mar 19, 2007 |
| Last update posted | Aug 10, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: